Skip to main content
. 2013 Dec 1;23(10):676–686. doi: 10.1089/cap.2012.0058

FIG. 2.

FIG. 2.

Mean change in weight and body mass index (BMI) Z-scores over time (open-label safety analysis set). (A) Mean change in weight. (B) Mean change in BMI Z-scores. RIS, risperidone; placebo/RIS, patients randomly assigned to placebo during double-blind (DB) phase who continued into open-label extension (OLE) and received risperidone; RIS low dose/RIS, patients randomly assigned to risperidone low dose during DB phase who continued into OLE and received risperidone; RIS high dose/RIS, patients randomly assigned to risperidone high dose during DB phase who continued into OLE and received risperidone.